Panacea Biotec Limited — Board Meeting, 30-05-2025: Outcome of Board Meeting

Panacea Biotec has announced a board meeting approving the consolidated financial results for the quarter and financial year ended March 31, 2025, with a net loss of Rs. 8.72 Cr versus Rs. 1.50 Cr last year. Revenue held steady at Rs. 559.09 Cr. The vaccines segment posted pre-tax losses, offset by gains in formulations. No dividend was declared given the losses. The Board approved appointing M/s R&D Company Secretaries as Secretarial Auditors for five years, pending shareholder approval. The company continues to secure key vaccine orders, including a Rs. 44 Cr UNICEF contract for bivalent oral polio vaccines.